A new drug in the class of sphingosine 1-phosphate receptor modulators for MS has been shown to be effective – and potentially safer than predecessors – in two trials published this week. If it goes on to gain regulatory approval, ozanimod will follow fingolimod (Gilenya) and siponimod (Mayzent) as a treatment of secondary progressive MS, ...
After fingolimod, more drugs in same class are close to approval for MS
By Michael Woodhead
5 Sep 2019